Documentary record · October 19, 2026 edition
Emcitate (tiratricol) — first treatment for peripheral thyrotoxicosis in MCT8 deficiency (Allan-Herndon-Dudley syndrome)
APPROVED.
SOURCE-VERIFIED · HUMAN REVIEW PENDING
Event date
September 28, 2026
Lifecycle state
APPROVED.
Source published
September 28, 2026
Source checked
October 19, 2026
Published on KPSGILL
- Approval: September 28, 2026, novel drug (Egetis). Evidence: a randomized placebo-controlled trial plus an open-label study.
- Status: APPROVED.
- Not established: any benefit on neurodevelopment. The indication is the peripheral thyrotoxicosis only.
Sources
- FDA press release Emcitate Primary · 2026-09-28 · checked 2026-10-19
Related on this site
Register: the record store · record id fda-emcitate-mct8-deficiency-2026-09-28 · SOURCE-VERIFIED · HUMAN REVIEW PENDING.